CRISPR-Cas3 Basic Patent Issued in Japan (Patent No. 7731156)

C4U Corporation (“C4U”) has been granted exclusive licenses, including sublicense rights, by the University of Osaka for the inventions related to CRISPR-Cas3, a unique genome editing technology. These include the invention titled “METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD” .
C4U is pleased to announce that the patent for this invention was issued in Japan on August 21, 2025 as Patent No. 7731156. 
This invention was initially patented in Japan (Patent No. 6480647), and its divisional applications were subsequently matured into Patent Nos. 7301332 and 7430358. In 2024, third parties filed oppositions to both patents, but in 2025 Japan Patent Office decided that they shoud be maintained. 
The latest patent, which matured from a further divisional application, steadily expands the scope of rights for the basic CRISPR-Cas3 system.  

The invention has also been patented outside of Japan, in Eurasia (Patent No. 040859), Korea (Patent No. 10-2541398), China (Patent No. ZL2018 8 0037636.X), Europe (Patent No. 3636753), Hong Kong (Patent No. 40021189), Australia (Patent No. 2018279457), Mexico (Patent No. 415175), and India (Patent No. 548919). Additionally, a grant eligibility notice has also been issued in Singapore and the United States.
C4U will continue strengthening its intellectual property portfolio with regard to CRISPR-Cas3 technology worldwide and accelerating its application in a wide range of fields, including pharmaceutical field.

About C4U Corporation
C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by the University of Osaka for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape.
https://www.crispr4u.jp/en/